• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

    3/26/26 7:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $HYPD alert in real time by email

    Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance

    Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL Tokens as of March 23(14)

    HYPD's Unique "Triple-Dip" HYPE Deployment Generated ~3x Base Staking Income in Q4

    Announces Executed LOI to Monetize the Optejet, With Potential Closing in Q2'26

    LAGUNA HILLS, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the fourth quarter and full year ending December 31, 2025.

    "Against a backdrop of significant market volatility, we are pleased to report rapid growth in our DeFi operating businesses which exceeded our guidance in the fourth quarter," said Hyunsu Jung, CEO of Hyperion DeFi. Mr. Jung continued, "Today, we are reporting detail on each business we have built in our first six months under our new DeFi strategy. We continue to make progress on our Company's corporate transformation as a premier institutional gateway to DeFi innovation, and we expect each business to continue to scale through 2026 and beyond. Hyperion DeFi is building for the future of on-chain finance. This is more than just HYPE."

    Q3'25 and Q4'25 Summary GAAP and Non-GAAP Financial Measures

    (Figures in $)Q3 2025Q4 2025
    GAAPRevenue302,506 496,229 
    Non-GAAPAdjusted Gross Profit(1)439,386 820,997 
    GAAPHYPE Digital Assets37,954,590 16,233,941 
    Non-GAAPGross HYPE Holdings(4)77,751,604 47,837,901 
    Non-GAAPNet Asset Value(9)74,545,583 44,154,737 
    GAAPSelling, General and Administrative Expense2,594,130 4,530,542 
    Non-GAAPOperating Expenses Excluding Stock-Based Compensation(5)4,315,016 3,007,135 
    GAAPNet Operating (Income) Expenses(4,125,685)39,958,264 
    Non-GAAPTreasury Gains (Losses)(6)11,868,872 (36,783,228)
    GAAPTotal Other Income (Expense), Net2,197,391 (288)
    Non-GAAPAdjusted Other Income (Expense)(7)(42,240)48,717 
    GAAPNet Income (Loss)6,625,582 (39,765,565)
    Non-GAAPAdjusted EBITDA(8)7,951,003 (38,920,649)



    All figures in this press release are not audited. Throughout this document, totals may not sum due to rounding. Calculations are based on unrounded results.

    This press release includes certain non-GAAP financial measures (including on a forward-looking basis) such as Adjusted Gross Profit, Gross HYPE Holdings, Net Asset Value, Operating Expenses Excluding Stock-Based Compensation, Treasury Gains (Losses), Adjusted Other Income (Expense), and Adjusted EBITDA. Please see "Footnotes" and "Non-GAAP Measures of Financial Performance" for reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures and important additional information.

    2025 Actuals &

    2026 Guidance

    (in $ millions)
    Q1'25AQ2'25AQ3'25AQ4'25AFY'25AFY'26

    Guidance
    2026

    Guidance


    vs. 2025

    Actual
    Adjusted Gross Profit(1)$0.01M$0.00M$0.44M$0.82M$1.28M$4M - $6M~4x



    Adjusted Gross Profit(1) By Operating Business Line (In $ Thousands)Q3'25Q4'25QoQ

    Growth
    Ecosystem Rewards-285>1000%
    DeFi Monetization<1102>1000%
    Yield Enhancement78792%
    Validator Commissions2149127%
    Staking Yield340305-10%

    Adjusted Gross Profit(1)43982187%
    Validator Commissions in HYPE(2)4581,362197%
    Staking Yield in HYPE(2)7,4378,71317%
    Effective Average HYPE Price In-Period(3)45.7635.12 
        

    Adjusted Gross Profit

    HYPD's "Triple-Dip" HYPE Development is Possible Because of Our Management's Unique Ability to Build on the Hyperliquid Blockchain

    HYPE Treasury Over TimeSeptember 30,

    2025
    December 31,

    2025
    March 23,

    2026(14)
    Gross HYPE Tokens(2)1.72 M1.88 M1.93 M
    HYPE Token Price$45.2$25.4$38.2
    Gross HYPE Holdings(4)$77.8 M$47.8 M$73.9 M
    Cash, Cash Equivalents,

    and USDH
    $8.2 M$6.5 M$9.2 M

    Please see "Footnotes" and "Non-GAAP Measures of Financial Performance" for reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures and important additional information.



    HYPD Investment Thesis

    We believe our Q4'25 results demonstrate that we have transcended the strategy and capabilities of a simple buy-and-hold "DAT" (digital asset treasury company), and instead, we are differentiated as the first U.S. publicly listed DeFi company building on the Hyperliquid blockchain.

    • We are unique among digital asset treasuries with five diversified operating business lines.
    • Our "Triple-Dip" HYPE deployment strategy, by which we earned approximately ~3x base staking income in Q4'25, is possible because of our management's unique ability to build on the Hyperliquid Blockchain.
    • We achieved +87% quarter-over-quarter growth in Adjusted Gross Profit(1), driven by new DeFi Monetization and Ecosystem Rewards strategies which were just beginning to ramp in Q4'25 (each at >1,000% Q-o-Q growth).
    • We operate with strong earnings leverage and a low cost base built for scale, and achieved (30%) quarter-over-quarter decline in Operating Expenses Excluding Stock-Based Compensation(5).
    • We anticipate $4M-$6M Adjusted Gross Profit(1) in 2026, ~4x our 2025 FY results.



    Our businesses are designed to simultaneously promote and monetize adoption of the Hyperliquid blockchain. In Q4, our unique ability to "triple-dip" our HYPE tokens across multiple deployment strategies generated ~3x the income would have otherwise generated from staking in isolation. Our "HYPD Triple-Dip" strategy is:

    1) Stake our HYPE

    2) Deploy the staked HYPE into another business activity – our Validator, Yield Enhancement, or DeFi Monetization, and

    3) Position ourselves to receive Ecosystem Rewards

    Adjusted Gross Profit(1) in Q3'25 and Q4'25

    Adjusted Gross Profit(1), a Non-GAAP Metric, aims to capture all of Hyperion DeFi's value-add operating business activities beyond simply buying and holding HYPE tokens. In total, Adjusted Gross Profit(1) increased +87% quarter-over-quarter from $439 thousand in Q3'25 to $821 thousand in Q4'25.

    Below is a summary of all six of our operating business activities included within Adjusted Gross Profit(1):

    1. Staking Yield: We stake our HYPE to our Validator and earn rewards.
      • In Q4'25, the Company earned 8,713 HYPE tokens from staking, up 17% quarter-over-quarter versus 7,437 in Q3'25.
      • On a dollar basis, our HYPE earned from staking generated $305 thousand Adjusted Gross Profit(1) in Q4'25 versus $340 thousand in Q3'25 (-10% quarter-over-quarter), given the Effective Average HYPE Price In-Period(3) declined from 45.76 in Q3'25 to 35.12 in Q4'25.
      • In Q4'25, we updated our Joint Validator structure which causes Staking Yield on third-party delegated HYPE tokens to our Validator to be added to our GAAP Revenue and Cost of Revenue on and after December 15, 2025. These components on third-party rewards offset to zero in Adjusted Gross Profit(1).
    2. Validator Commissions: The Company operates its Validator under a Joint Validator Operators Agreement (together with Kinetiq and Pier Two) and earns commissions on rewards delivered to third-party tokens delegated to the Validator.
      • 11.8 million HYPE tokens were delegated to our Validator as of December 31, 2025, which is +43% versus 8.2 million delegated as of September 30, 2025.
      • In Q4'25, the Company earned 1,362 HYPE tokens as validator commissions, up 197% quarter-over-quarter versus 458 in Q3'25.
      • On a dollar basis, our HYPE earned from validator commissions generated $49 thousand Adjusted Gross Profit(1) in Q4'25 versus $21 thousand in Q3'25 (+127% quarter-over-quarter), given the Effective Average HYPE Price In-Period(3) declined from 45.76 in Q3'25 to 35.12 in Q4'25.
      • In Q4'25, we updated our Joint Validator structure which causes Validator Commissions owed to our partners Kinetiq and Pier Two to be added to our GAAP Revenue and Cost of Revenue on and after December 15, 2025. These components on third-party commissions offset to zero in Adjusted Gross Profit(1).
    3. Yield Enhancement: The Company pursues accretive strategies to enhance yield earned on its tokens.
      • Yield Enhancement activities generated $79 thousand Adjusted Gross Profit(1) in Q4'25 versus $78 thousand in Q3'25 (+2% quarter-over-quarter).
      • Q4'25 and Q3'25 Yield Enhancement activities included selling covered call options on the price of HYPE to institutional counterparties, collateralized by the Company's LSTs.
      • In Q1'26, we announced a partnership with Rysk to launch an Institutional Volatility Income Vault, further optimizing our Yield Enhancement capabilities while building the infrastructure to accommodate third-party HYPE tokens within the Vault in the future.
    4. DeFi Monetization: The Company supports and monetizes Hyperliquid DeFi activity with sustainable, scalable practices.
      • DeFi Monetization activity generated $102 thousand Adjusted Gross Profit(1) in Q4'25 versus less than $1 thousand Q3'25, as our new strategies began to ramp.
      • DeFi Monetization includes our Temporary HYPE Asset Use Agreements and protocol partnerships.
      • Trading volumes on our Felix-partner markets cumulatively exceeded $2.8 billion as of March 23, 2026(14).
      • In Q1'26, we announced a partnership with the HyperLend protocol to create a whitelisted lending pool native to the HyperEVM network whereby we can borrow on-chain via smart contracts at a rate significantly below our existing borrowing costs (4.0% vs. 8.0%). In addition, we expect to selectively open the pool to third-party participants over time, generating additional diversified fee income opportunities for us.
      • In Q1'26, the Company entered into a HYPE Asset Use Service Agreement with Silhouette AG ("Silhouette"). The Company agreed to link 100,000 of its owned and staked HYPE tokens to the trading wallet of Silhouette, allowing Silhouette and its customers to receive reduced trading fees on the Hyperliquid decentralized exchange, and entitling the Company to earn a portion of those fee savings as income, plus 100% of staking rewards.
    5. Ecosystem Rewards: Through our active participation in the Hyperliquid DeFi ecosystem, the Company positions itself for the receipt of future potential token airdrops, protocol incentives, and other rewards that may become available periodically.
      • Ecosystem Rewards generated $285 thousand Adjusted Gross Profit(1) in Q4'25, versus none in Q3'25.
      • In November 2025, we received 1,918,478 KNTQ tokens in Kinetiq's airdrop token generation event.
      • As of March 23, 2026, Q1 QTD we have received 1,000,000 HPL tokens from Hyperlend in connection with our on-chain credit pool partnership.
      • Given our partnerships with other Hyperliquid ecosystem participants such as Rysk, Felix, and Silhouette, and given that we are continuing to accrue additional Kinetiq points, we anticipate additional ecosystem rewards in 2026.
    6. Life Sciences: Hyperion DeFi continues to develop its proprietary Optejet User Filled Device (UFD).
      • Life Sciences did not generate any Adjusted Gross Profit(1) in Q4'25 or Q3'25.
      • In Q1'26, we executed a non-binding Letter of Intent (LOI) to monetize the Optejet, our last remaining product within the Life Sciences segment, and the transaction may close in Q2'26.



    Non-GAAP Income Summary

    (In $ Thousands)
    Q3'25Q4'25
    Adjusted Gross Profit(1)439821
    Operating Expenses Excluding Stock-Based Compensation(5)4,3153,007
    Treasury Gains (Losses)(6)11,869(36,783)
    Adjusted Other Income (Expense)(7)(42)49
    Adjusted EBITDA(8)7,951(38,921)

    Please see "Footnotes" and "Non-GAAP Measures of Financial Performance" for reconciliations of non-GAAP financial measures to the most directly comparable GAAP financial measures and important additional information.



    Q3'25 and Q4'25 Expense Summary Results

    • Operating Expenses Excluding Stock-Based Compensation(5) declined (30%) quarter-over-quarter from $4.3 million in Q3'25 to $3.0 million in Q4'25.
    • Research and development expenses declined (49%) quarter-over-quarter from $374 thousand in Q3'25 to $189 thousand in Q4'25.
    • Selling, general, and administrative expenses excluding stock-based compensation decreased (28%) quarter-over-quarter, from $3.9 million in Q3'25 to $2.3 million in Q4'25.



    Q3'25 and Q4'25 Treasury Summary

    • Gross HYPE Tokens(2) increased from 1.72 million as of Q3'25 to 1.88 million as of Q4'25.
      • Our HYPE treasury position has grown to over 1.93 million tokens as of March 23, 2026(14).
    • Gross HYPE Holdings(4) decreased from $77.8 million as of Q3'25 to $47.8 million as of Q4'25 as the price of HYPE declined from $45.19 to $25.43 in Q4'25.
    • Net Asset Value(9) decreased from $74.5 million as of Q3'25 to $44.2 million as of Q4'25.
    • Treasury Gains (Losses)(6) was ($36.8 million) in Q4'25 versus $11.9 million in Q3'25.



    Q3'25 and Q4'25 Net Income (Loss) and Adjusted EBITDA(8)

    • Q4'25 Net Loss of ($39.8 million) compares to Q3'25 Net Income of $6.6 million.
    • Q4'25 Adjusted EBITDA of ($38.9 million) compares to Q3'25 Adjusted EBITDA of $8.0 million.
    • Q4'25 Net Loss Attributable to Common Shareholders of ($40.6 million) compares to Q3'25 Net Income Attributable to Participating Securities of $5.8 million.
    • Q4'25 Net Loss per Share was ($6.29) on 6,452,733 on weighted average shares outstanding; compared to Q3'25 Net Income per Common Share of $0.26 on a basic basis (6,027,713 weighted average shares) and $0.05 on a diluted basis (28,951,915 weighted average shares)



    FY'25 Cash Flows Summary

    • Net Cash Used in Operating Activities declined from $30.1 million in FY'24 to $14.8 million in FY'25 (of which $4.1 million was in Q4'25).
      • Our cash, cash equivalents, and USDH exceed $9.2 million as of March 23, 2026(14).
    • Net Cash Used in Investing Activities increased from $0.2 million in FY'24 (purchase of property and equipment) to $72.0 million in FY'25 (purchase of digital assets, of which $6.3 million was in Q4'25).
    • Net Cash Provided by Financing Activities increased from $17.6 million in FY'24 to $91.0 million in FY'25.
      • Net cash provided by financing activities for the year ended December 31, 2025 totaled approximately $91.0 million, which was primarily attributable to $49.4 million of net proceeds from the sale of Series A Preferred Stock and warrants in the Private Placement, $39.4 million of net proceeds from the sale of common stock in our "at-the-market" offering (of which $9.4 million was in Q4'25) and $4.8 million of net proceeds from the exercise of stock warrants partially offset by $1.5 million from the repayment of notes payable and $0.9 million from payment of preferred dividends.
      • Net cash provided by financing activities for the year ended December 31, 2024 totaled approximately $17.6 million, which was primarily attributable to $17.0 million of net proceeds from the sale of common stock and warrants in equity offerings and, $6.1 million of net proceeds from the sale of common stock in our "at-the-market" offering, partially offset by $5.5 million from the repayment of notes payable.



    FY'25 Summary Financial Results

    • Revenue increased substantially from $57 thousand in FY'24 to $0.8 million in FY'25.
    • Research and development expenses declined (87%) year-over-year from $14.5 million in FY'24 to $1.9 million in FY'25.
    • Selling, general, and administrative expenses increased 20% year-over-year from $14.3 million in FY'24 to $17.2 million in FY'25.
    • Net Loss declined (9%) year-over-year from ($49.8 million) in FY'24 to ($45.3 million) in FY'25.
    • Net Loss Attributable to Common Stockholders declined (6%) year-over-year from ($49.8 million) in FY'24 to ($47.0 million) in FY'25.
    • Net Loss per Share – Basic and Diluted of ($59.81) in FY'24 compares to ($9.40) in FY'25, on 832,997 weighted average shares (basic and diluted) in FY'24 versus 5,000,331 in FY'25.



    Conference Call & Webcast

    Hyperion DeFi, Inc. will host a conference call to discuss fourth quarter and full year 2025 results at 8:00 a.m. Eastern Time on March 26, 2026. A slide presentation that includes supplemental financial information and reconciliations of certain non-GAAP measures to their most directly comparable GAAP measures can be accessed through the Company's Investor Relations website at https://ir.hyperiondefi.com/events-and-presentations along with information for the conference call. Participants may also submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through April 6, 2026 at 11:59 p.m. Eastern Time on the Company's website.

    Presentation

    All growth rates represent quarter-over-quarter comparisons, except as otherwise noted. All amounts in tables are presented in U.S. dollars, rounded to the nearest dollar, except as otherwise noted. As a result, certain amounts and rates may not sum or recalculate using the rounded dollar amounts provided. All numbers in this press release are not audited.

    About the Hyperliquid Platform and the HYPE Token

    Hyperliquid is a next-generation layer one blockchain optimized for high frequency, transparent trading. The blockchain includes fully on-chain perpetual futures and spot order books, with every order, cancel, trade, and liquidation occurring within 70 millisecond block times. It also hosts the HyperEVM, a general-purpose smart contract platform that supports permissionless decentralized financial applications akin to Ethereum.

    HYPE is the native token of Hyperliquid. Staked HYPE provides utility for users via reduced trading fees and increased referral bonuses. As of March 2026, more than 41 million HYPE have been autonomously purchased and sequestered by the blockchain with the trading fees generated on the network's central limit order books.

    About Hyperion DeFi, Inc.

    Hyperion DeFi, Inc. is the first U.S. publicly listed DeFi company building on Hyperliquid. The Company provides investors with streamlined access to the Hyperliquid ecosystem, one of the fastest growing, highest revenue-generating blockchains in the world. Shareholders benefit from compounding exposure to HYPE, both from its native staking yield and additional revenues generated from its unique on-chain utility.

    Hyperion DeFi is also developing its proprietary Optejet User Filled Device that is designed to work with a variety of topical ophthalmic liquids, including artificial tears and lens rewetting products. The Optejet is especially useful in chronic front-of-the-eye diseases due to its ease of use, enhanced safety and tolerability, and potential for superior compliance versus standard eye drops. Together, these benefits may result in higher treatment compliance and better outcomes for patients and providers.

    For more information, please visit Hyperiondefi.com or follow @hyperiondefi on X.

    Forward Looking Statements; Disclaimer

    Except for historical information, all the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements, our future activities or other future events or conditions, including the viability of, and risks associated with, our cryptocurrency treasury strategy, the growth and revenue potential of the Hyperliquid ecosystem and the growth prospects of the Company. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission.

    Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Hyperion DeFi does not undertake any obligation to update any forward-looking statements.

    Certain information contained in this press release relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Hyperion DeFi's own internal estimates and research. While Hyperion DeFi believes these third-party studies, publications, surveys and other data to be reliable as of the date of this press release, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the reasonableness or accuracy of Hyperion DeFi's internal estimates or research and no reliance should be made on any information or statements made in this press release relating to or based on such internal estimates and research. You should conduct your own investigation and analysis of Hyperion DeFi, its business, prospects, results of operations and financial condition. In furnishing this information, Hyperion DeFi does not undertake any obligation to provide you with access to any additional information (including forward-looking information and any projections contained herein) or to update or correct the information.

    Hyperion DeFi, Inc. Investor Contact:

    Jason Assad

    Hyperion DeFi, Inc.

    [email protected]

    (678) 570-6791



    Hyperion DeFi, Inc.

    Balance Sheets

         
      December 31,  December 31, 
      2025  2024 
    Assets      
    Current Assets      
    Cash and cash equivalents $6,443,467  $2,121,463 
    Prepaid expenses and other current assets  802,342   645,736 
        Total Current Assets  7,245,809   2,767,199 
           
    Digital assets  16,345,347   — 
    Digital assets receivable, net  6,935,131   — 
    Digital intangible assets  20,591,555   — 
    Operating lease right-of-use asset  415,998   718,360 
    Other assets  230,416   182,200 
        Total Assets $51,764,256  $3,667,759 
           
    Liabilities and Stockholders' Equity (Deficit)      
    Current Liabilities:      
    Accounts payable $317,900  $1,954,681 
    Accrued former licensor obligations  —   2,245,087 
    Accrued expenses and other current liabilities  1,871,106   1,322,674 
    Operating lease liabilities - current portion  512,007   575,163 
    Notes payable - current portion, net of debt discount of $0 and $527,870 as of December 31, 2025 and

       December 31, 2024, respectively
      —   5,212,532 
    Convertible notes payable - net of debt discount of $0 and $263,930 as of December 31, 2025 and

       December 31, 2024, respectively
      —   4,736,070 
        Total Current Liabilities  2,701,013   16,046,207 
           
    Notes payable - non-current portion, net of debt discount of $543,230 and $0 as of December 31, 2025

       and December 31, 2024, respectively
      7,796,136   — 
    Operating lease liabilities, non-current portion  206,600   717,504 
        Total Liabilities  10,703,749   16,763,711 
           
    Commitments and contingencies (Note 11)      
           
    Stockholders' Equity (Deficit):      
    Preferred stock, $0.0001 par value, 60,000,000 shares authorized; Series A Non-Voting Convertible

       Preferred Stock, 5,435,898 shares designated, and 5,435,897 and 0 shares issued and outstanding as

       of December 31, 2025 and December 31, 2024, respectively, with a liquidation preference of

       $50,795,000 as of December 31, 2025
      544   — 
    Common stock, $0.0001 par value, 600,000,000 shares authorized; 8,762,329 shares issued and

       8,680,005 shares outstanding as of December 31, 2025 and 1,506,369 shares issued and outstanding

       as of December 31, 2024
      876   151 
    Additional paid-in capital  281,937,072   182,213,889 
    Treasury stock, at cost, 82,324 shares as of December 31, 2025  (253,558)  — 
    Accumulated deficit  (240,624,427)  (195,309,992)
    Total Stockholders' Equity (Deficit)  41,060,507   (13,095,952)
    Total Liabilities and Stockholders' Equity (Deficit) $51,764,256  $3,667,759 





    Hyperion DeFi, Inc.

    Statements of Operations
       
      For the Year Ended
      December 31, 
      2025  2024 
    Revenue $813,455  $57,336 
    Cost of revenue  (303,290)  (3,927,228)
    Gross Profit (Loss)  510,165   (3,869,892)
           
    Operating (Income) Expenses:      
    Research and development  1,910,430   14,462,722 
    Selling, general and administrative  17,175,698   14,333,114 
    Realized gain - digital assets  (8,321,844)  — 
    Unrealized loss - digital assets  9,030,413   — 
    Impairment loss - digital assets  27,188,768   — 
    Impairment loss - other assets  —   11,207,897 
    Gain on covered call option  (157,570)  — 
    Provision for credit losses  405,331   — 
    Reacquisition of license rights  —   4,864,600 
        Net Operating Expenses  47,231,226   44,868,333 
        Loss From Operations  (46,721,061)  (48,738,225)
           
    Other Income (Expense):      
    Other income (expense), net  389,685   (90,601)
    Gain on extinguishment of liabilities  2,334,711   — 
    Change in fair value of equity consideration payable  —   1,240,800 
    Interest expense  (1,557,788)  (2,484,431)
    Interest income  240,018   254,024 
      Total Other Income (Expense), Net  1,406,626   (1,080,208)
           
    Net Loss  (45,314,435)  (49,818,433)
    Dividend to preferred stockholders  (1,684,783)  — 
    Net Loss Attributable to Common Stockholders $(46,999,218) $(49,818,433)
           
    Net Loss per Share - Basic and Diluted $(9.40) $(59.81)
           
    Shares Outstanding - Basic and Diluted  5,000,331   832,997 





    Hyperion DeFi, Inc.

    Statements of Changes in Stockholders' (Deficit) Equity
       
      For the Years Ended December 31, 2025 and 2024
                           Total
                Additional        Stockholders'
      Preferred Stock Common Stock Paid-In Treasury Stock Accumulated (Deficiency)
      Shares Amount Shares Amount Capital Shares Amount Deficit Equity
    Balance - January 1, 2024 — $— 569,409  $57  154,490,596  — $—  $(145,491,559) $8,999,094 
    Issuance of common stock in At the Market Program [1] —  — 70,381   7  6,047,362  —  —   —   6,047,369 
    Issuance of common stock as consideration for licensing agreement [2] —  — 7,668   1  436,808  —  —   —   436,809 
    Issuance of common stock as consideration for reacquisition of licensing agreement [3] —  — 28,742   3  2,322,388  —  —   —   2,322,391 
    Issuance of common stock and warrants in offerings [4] —  — 653,493   66  17,011,256  —  —   —   17,011,322 
    Exercise of pre-funded stock warrants —  — 152,905   15  1,208  —  —   —   1,223 
    Warrant modification and additional warrants - incremental value [5] —  — —   —  2,868,000  —  —   —   2,868,000 
    Warrant modification and additional warrants - in issuance costs for offering [6] —  — —   —  (2,868,000) —  —   —   (2,868,000)
    Issuance of common stock as consideration for modification of loan agreement —  — 23,771   2  199,998  —  —   —   200,000 
    Stock-based compensation:                        
    Amortization of stock option awards —  — —   —  1,454,946  —  —   —   1,454,946 
    Amortization of restricted stock units —  — —   —  249,327  —  —   —   249,327 
    Net loss —  — —   —  —  —  —   (49,818,433)  (49,818,433)
    Balance - December 31, 2024 —  — 1,506,369   151  182,213,889  —  —   (195,309,992)  (13,095,952)
    Issuance of preferred stock and warrants in private placement [7] 5,435,897  544 —   —  49,365,206  —  —   —   49,365,750 
    Issuance of common stock in At the Market offering [8] —  — 5,607,759   561  39,357,243  —  —   —   39,357,804 
    Issuance of common stock from exercise of warrants [9] —  — 502,125   50  3,892,423  —  —   —   3,892,473 
    Induced exercise of stock warrants [10] —  — 197,118   19  922,731  —  —   —   922,750 
    Warrants issued in consideration for debt modification —  — —   —  858,270  —  —   —   858,270 
    Issuance of common stock from the partial conversion of note payable —  — 404,820   41  640,295  —  —   —   640,336 
    Issuance of common stock from the delivery of vested restricted stock units —  — 529,297   53  (53) —  —   —   — 
    Shares withheld for employee payroll taxes —  — —   —  —  82,324  (253,558)  —   (253,558)
    Reverse stock split settlement of fractional shares —  — (41)  —  (160) —  —   —   (160)
    Stock-based compensation:                        
    Amortization of stock option awards —  — —   —  533,062  —  —   —   533,062 
    Amortization of restricted stock units —  — —   —  5,785,548  —  —   —   5,785,548 
    Issuance of common stock to vendors in consideration for service provided —  — 14,882   1  53,401  —  —   —   53,402 
    Net loss —  — —   —  —  —  —   (45,314,435)  (45,314,435)
    Preferred stock dividend ($0.59 per preferred share outstanding) —  — —   —  (1,684,783) —  —   —   (1,684,783)
    Balance - December 31, 2025 5,435,897 $544 8,762,329  $876 $281,937,072  82,324 $(253,558) $(240,624,427) $41,060,507 

    ____________________________________

    [1] Includes gross proceeds of $6,234,402 less total issuance costs of $187,033.

    [2] Shares issued as partial consideration for License Agreement with Formosa Pharmaceuticals Inc.

    [3] Shares issued as partial consideration for reversion of License Agreement with Bausch & Lomb Ireland Limited.

    [4] Includes gross proceeds of $19,385,015, less total cash issuance costs of $2,373,693.

    [5] Offering includes modification of warrants and additional warrants in the July 2024 offering.

    [6] Non-cash warrant modification and additional warrants issuance costs related to one of the offerings are shown on a separate line item for clarity.

    [7] Includes gross proceeds of $50,000,000 less total issuance costs of $634,250.

    [8] Includes gross proceeds of $40,645,265 less total issuance costs of $1,287,461.

    [9] Partial exercise of the Armistice warrants.

    [10] Includes gross proceeds of $1,039,206 less total issuance costs of $116,456. Also note that incremental value and non-cash warrant modification and additional warrants issuance costs related to the warrant inducement entered into on January 16, 2025 offset to a zero balance. See Note 10 – Stockholders' Equity (Deficiency).



    Hyperion DeFi, Inc.

    Statements of Cash Flows
       
      For the Year Ended
      December 31, 
      2025  2024 
    Cash Flows From Operating Activities      
    Net loss $(45,314,435) $(49,818,433)
    Adjustments to reconcile net loss to net cash and cash equivalents used in operating activities:      
    Stock-based compensation  6,372,012   1,704,273 
    Change in fair value of equity consideration payable  —   (1,240,800)
    Depreciation of property and equipment  —   1,128,449 
    Amortization of debt discount  655,997   759,049 
    Asset impairments  —   11,207,897 
    Write-down of inventories to net realizable value  —   3,085,450 
    Reacquisition of license rights  —   2,864,600 
    Non-cash lease expense  302,362   528,359 
    Gain on extinguishment of liabilities  (2,334,711)  — 
    Non-cash realized gain - digital assets  (3,754,493)  — 
    Unrealized loss - digital assets  9,030,413   — 
    Impairment loss - digital assets  22,621,417   — 
    Staking income  (554,098)  — 
    Non-cash commission paid to co-validators  26,139   — 
    Provision for credit losses  405,331   — 
    Unamortized non-refundable upfront fee on digital asset receivable  307,278   — 
    Interest expense added to note principal  379,998   — 
    Changes in operating assets and liabilities:      
    Prepaid expenses and other current assets  (156,587)  554,020 
    License fee and expense reimbursement receivables  —   99,006 
    Deferred clinical supply costs  —   868,328 
    Security and equipment deposits  (48,215)  1,506 
    Accounts payable  (1,636,781)  446,596 
    Accrued compensation  —   (1,514,452)
    Accrued expenses and other current liabilities  (497,741)  (293,579)
    Lease liabilities  (574,060)  (501,250)
    Net Cash and Cash Equivalents Used In Operating Activities  (14,770,174)  (30,120,981)
           
    Cash Flows From Investing Activities      
    Purchase of property and equipment  —   (161,477)
    Purchase of productive digital assets  (71,954,039)  — 
    Net Cash and Cash Equivalents Used In Investing Activities  (71,954,039)  (161,477)
           
    Cash Flows From Financing Activities      
    Proceeds from sale of common stock and warrants in direct offering  —   19,385,015 
    Proceeds from sale of preferred stock and warrants in private placement  50,000,000   (2,373,693)
    Payment of private placement issuance costs  (634,250)  — 
    Proceeds from sale of common stock in At the Market offering  40,645,265   6,234,402 
    Payment of issuance costs for At the Market offering  (1,287,461)  (187,033)
    Proceeds from exercise of stock warrants  3,892,473   1,223 
    Proceeds from induced exercise of stock warrants  1,039,206   — 
    Payment of cash issuance costs for induced exercise of stock warrants  (116,456)  — 
    Reverse stock split settlement of fractional shares  (160)  — 
    Repayments of notes payable  (1,463,437)  (5,505,050)
    Payment of preferred dividend  (892,167)  — 
    Payment of costs in connection with debt extinguishment  (136,796)  — 
    Net Cash and Cash Equivalents Provided By Financing Activities  91,046,217   17,554,864 
    Net Increase (Decrease) in Cash and Cash Equivalents  4,322,004   (12,727,594)
    Cash and Cash Equivalents - Beginning of Period  2,121,463   14,849,057 
    Cash and Cash Equivalents - End of Period  $6,443,467  $2,121,463 





    Hyperion DeFi, Inc.

    Statements of Cash Flows, continued
       
      For the Year Ended
      December 31, 
      2025 2024
    Supplemental Disclosure of Cash Flow Information:      
    Cash paid during the period for:      
    Interest $481,360 $1,622,479
    Taxes $— $—
           
    Supplemental Disclosure of Non-Cash Investing and Financing Activities      
    Deposits of HYPE into liquid staking activities $58,753,773 $—
    Redemption of liquid staking tokens for HYPE $15,675,801 $—
    Transfer of HYPE to digital asset receivable $9,922,239 $—
    Accrued dividend payable $792,616 $—
    Purchase of insurance policy financed by note payable $— $505,050
    Accrual for intangible asset milestone obligation $— $2,000,000
    Reclassification of deferred clinical supply costs to inventories $— $2,975,652
    Modification date carrying value of extinguished Avenue Loan $10,262,280 $—
    Modification date fair value of modified Avenue Loan $10,172,657 $—
    Warrants issued for debt modification $858,270 $—
    Warrant modification and additional warrants - incremental value $1,194,102 $2,868,000
    Common stock issued in consideration for equipment received in conjunction with licensing agreement $— $135,400
    Conversion of Avenue Loan to common stock $640,336 $—
    Common stock issued in consideration for licensing agreement $— $436,809
    Common stock issued in consideration for reacquisition of licensing agreement $— $2,322,391
    Common stock issued as consideration for modification of loan agreement $— $200,000
    Interest expense added to note principal $367,308 $102,902
    Issuance of common stock related to vested restricted stock units $53 $—
    Treasury stock held for employee payroll taxes upon the delivery of restricted stock units $253,558 $—



    Hyperion DeFi Non-GAAP Measures of Financial Performance and Supplemental Disclosures

    Reconciliation of GAAP Revenue to Non-GAAP Adjusted Gross Profit(1) (unaudited)
       
     For the Three

    Months Ended
    For the Three

    Months Ended
     September 30,

    2025
    December 31,

    2025
    Revenue $302,506 $496,229
    Subtract: Cost of Revenue- ($303,242)
    Add: Accumulated but unrealized staking yield on LSTs(10)$58,771$172,463
    Add: Operating Income from yield enhancement strategies$78,109$79,461
    Add: Realized gains – digital assets from ecosystem rewards- $285,450
    Add: Interest Income from DeFi Monetization activity- $90,636
    Adjusted Gross Profit(1)$439,386 $820,997

    Note: See "Footnotes" section for detailed explanations and definitions.



    Q4'25 Reconciliation of GAAP HYPE Digital Assets to Non-GAAP Gross HYPE Holdings(4) (unaudited)
      
     



    As of December 31, 2025
    Value $Token

    Count
     Token

    Price
    HYPE - Digital Assets16,233,941  638,352 $ 25.43
    Add:     
    HYPE digital asset receivable*7,647,740 300,725 $25.43
    HiHYPE at carrying value8,437,277 398,277 $21.18
    kHYPE at carrying value11,369,458 505,434 $22.49
    kmHYPE at carrying value649,820 28,888 $22.49
    Add: Unrealized accretion (dilution) expected upon future LST to HYPE Token reconversion(11)3,499,665 9,410 N.M.**
    Gross HYPE Holdings(4)47,837,901     
    Gross HYPE Tokens(2)  1,881,086 $ 25.43
    Note: See "Footnotes" section for detailed explanations and definitions.



    Unrealized accretion (dilution) expected upon LST to HYPE reconversion as of Q3'25

    4,912,082    
          
    In-Period Change in unrealized accretion (dilution) expected upon LST to HYPE vs. Q3'25

    (1,412,417)    
          

    *Presented gross of $405,331 provision for credit losses and $307,278 unamortized nonrefundable upfront fee.

    **Throughout this release, N.M. is the abbreviation for "Not Meaningful".



    Q3'25 Reconciliation of GAAP HYPE Digital Assets to Non-GAAP Gross HYPE Holdings(4) (unaudited)
      
     



    As of September 30, 2025
    Value $ Token

    Count
     Token

    Price
    HYPE digital assets37,954,590  839,889 $45.19
    Add: HiHYPE at Carrying Value34,884,932 877,871 $39.74
    Add: Unrealized accretion (dilution) expected upon future LST to HYPE Token reconversion(11)4,912,082 2,788 N.M.
    Gross HYPE Holdings(4)77,751,604     
    Gross HYPE Tokens(2)  1,720,549 $45.19
    Note: See "Footnotes" section for detailed explanations and definitions.



    Unrealized accretion (dilution) expected upon LST to HYPE reconversion as of June 30, 2025*

    4,912,082    
          

    *The Company did not hold any LSTs on or prior to June 30, 2025. Therefore, as of September 30, 2025, the in-period change in unrealized accretion (dilution) expected upon LST to HYPE Token Reconversion is the same as the absolute figure.



    Reconciliation of GAAP Selling, General and Administrative expense to Non-GAAP

    Operating Expense Excluding Stock-Based Compensation
    (5) (unaudited)
        
     For the Three Months Ended

    September 30, 2025
     For the Three Months Ended

    December 31, 2025
    Selling, general and administrative expense$2,594,130  $4,530,542  
    Subtract: stock-based compensation expense$1,347,031 ($1,712,361) 
    Add: research and development expense$373,855 $188,954 
    Operating Expense Excluding Stock-Based Compensation(5)$4,315,016  $3,007,135  

    Note: See "Footnotes" section for detailed explanations and definitions.



    Supplemental Disclosure of Disaggregated Stock-Based Compensation (unaudited)
       
    ($ in Thousands)For the Three Months Ended

    September 30, 2025
    For the Three Months Ended

    December 31, 2025
    Mark-to-market adjustment of vested but undelivered stock-based compensation(2,140)

    -
    Amortized expensing of unearned executive milestone awards210998
    All remaining stock-based compensation583715
    Total Stock-Based Compensation(1,347)

    1,712



    Reconciliation of GAAP Net Operating (Expenses) Income to Non-GAAP Treasury Gains (Losses)(6) (unaudited)
       
     For the Three Months Ended

    September 30, 2025
    For the Three Months Ended

    December 31, 2025
    Net Operating (Expenses) Income$4,125,685 ($39,958,264)

     
    Add Back:  
    Research and development expense$373,855 $188,954 
    Selling, general and administrative expense$2,594,130 $4,530,542 
    Provision for credit losses- $405,331 
    In-Period change in unrealized accretion (dilution) upon LST to HYPE reconversion$4,912,082 ($1,412,417)

     
    Subtract:  
    Accumulated but unrealized staking yield on LSTs(10)($58,771)

     ($172,463)

     
    Operating income from airdrops- ($285,450)

     
    Operating income from yield enhancement strategies($78,109)

     ($79,461)

     
    Treasury Gains (Losses)(6)$11,868,872 ($36,783,228)

     

    Note: See "Footnotes" section for detailed explanations and definitions.



    Reconciliation of GAAP Total Other Income (Expense), Net to Non-GAAP Adjusted Other Income (Expense)(7) (unaudited)
       
     For the Three Months Ended

    September 30, 2025
    For the Three Months Ended

    December 31, 2025
    Total Other Income (Expense), Net$2,197,391 ($288)

     
    Add Back:  
    Interest expense$223,080 $224,799 
    Reduction in life sciences liabilities(12)($2,407,154)

     - 
    Other non-recurring items(13)($55,557)

     ($85,158)

     
    Subtract: Interest income from DeFi Monetization activity- ($90,636)

     
    Adjusted Other Income (Expense)(7)($42,240)

     $48,717 

    Note: See "Footnotes" section for detailed explanations and definitions.



    Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA(8) (unaudited)
       
     For the Three Months EndedFor the Three Months Ended
     September 30, 2025December 31, 2025
    Net Income$6,625,582 ($39,765,565)

     
    Add back:  
    Stock-based compensation($1,347,031) $1,712,361 
    Interest expense$223,080 $224,799 
    Provision for credit losses- $405,331 
    Income Taxes- - 
    Depreciation and amortization expense*- - 
    Reductions in life sciences liabilities(12)($2,407,154)

     - 
    Other non-recurring items(13)($55,557)

     ($85,158)

     
    Add: In-period change in unrealized accretion (dilution) expected upon LST to HYPE reconversion$4,912,082 ($1,412,417)

     
    Adjusted EBITDA(8)$7,951,003 ($38,920,649)

     

    Note: See "Footnotes" section for detailed explanations and definitions.

    *Does not include Amortization of Operating Lease.



    Reconciliation of GAAP HYPE digital assets, as adjusted to Gross HYPE Holdings(4), to Non-GAAP Net Asset Value(9) (unaudited)
       
     As ofAs of
     September 30,

    2025
    December 31,

    2025
    HYPE digital assets, as adjusted to Gross HYPE Holdings(4)$77,751,604 $47,837,901 
    Add: KNTQ digital assets- $111,406 
    Add: Current Assets$9,085,767 $7,245,809 
    Subtract: Current Liabilities($4,037,092)

     ($2,701,013)

     
    Subtract: Notes Payable*($8,254,696)

     ($8,339,366)

     
    Net Asset Value(9)$74,545,583 $44,154,737 

    Note: See "Footnotes" section for detailed explanations and definitions.

    *Non-current portion; does not subtract debt discount of $598,691 as of September 30, 2025 or $543,230 as of December 31, 2025.



    Footnotes

    1. "Adjusted Gross Profit" is a non-GAAP measure. Adjusted Gross Profit is defined as all in-period gross profit generated by the Company's operations excluding buying digital assets and associated mark-to-market price movements. Such activities include staking yield, validator operations, yield enhancement activity, DeFi monetization partnerships, ecosystem rewards, and life sciences operations. It is reconciled to the GAAP measure "Revenue" by (i) subtracting Cost of Revenue, (ii) adding accumulated but unrealized staking yield on LSTs, (iii) adding the portion of GAAP operating income which was generated from yield enhancement strategies (such as selling covered calls), (iv) adding the portion of GAAP "Realized gains – digital assets" generated from ecosystem rewards such as the receipt of airdrop tokens, and (v) adding the portion of GAAP "Interest Income" generated from digital assets receivables. We believe "Adjusted Gross Profit" is a helpful financial measure to our management and investors as it aims to capture all in-period gross profit generated by our active operational strategies without the impact of (i) the temporary GAAP earnings volatility of HYPE to LST conversion and LST to HYPE reconversion, (ii) dispersed GAAP presentment of our operational strategies across various Statements of Operations sections, or (iii) the impacts of realized or unrealized gains or losses on our digital assets. We believe Adjusted Gross Profit is a critical metric to quantify and compare our core operational activities between periods.
    2. The following are unaudited supplemental operating disclosures: Gross HYPE Tokens, the number of HYPE tokens staked at the Kinetiq x Hyperion Validator, Validator Commissions in HYPE, and Staking Yield in HYPE.
    3. Calculated as the sum of the in-period Non-GAAP Adjusted Gross Profit components of (a) Validator Commissions plus (b) Staking Yield (such figures being expressed in-period in US Dollars), divided by the sum of (c) Validator Commissions in HYPE plus (d) Staking Yield in HYPE.
    4. "Gross HYPE Holdings" is a non-GAAP measure. Gross HYPE Holdings is defined as the gross market value of the Company's HYPE assuming (a) all temporary HYPE token use agreements are exited and (b) all LSTs were converted back to HYPE tokens as of the end of each respective reporting quarter. It is reconciled to the GAAP measure "HYPE digital assets" by adding (i) HYPE digital assets receivable (without subtracting provisions for credit losses or unamortized nonrefundable upfront fees), (ii) HYPE LSTs at carrying value (including without limitation HiHYPE, kHYPE, and kmHYPE) and (iii) the unrealized accretion (dilution) expected upon LST to HYPE reconversion as of the end of each respective reporting quarter. We believe Gross HYPE Holdings is a helpful non-GAAP financial measure to our management and investors because it eliminates the temporary HYPE value impacts caused by our DeFi Monetization token movements as well as the conversion and reconversion between HYPE tokens and LSTs, which (a) causes staking yield on our LSTs not to be recognized in-period in accordance with GAAP and (b) does not recognize upward mark-to-market movements in underlying HYPE tokens given LSTs are carried at the lower of cost basis or impaired value. As such, it provides useful information about our balance sheet, allows for greater transparency with respect to important metrics used by our management for financial, risk management and operational decision-making, and provides an additional tool for investors to understand and compare our operating results across reporting periods.
    5. "Operating Expenses Excluding Stock-Based Compensation" is a non-GAAP measure. Operating Expenses Excluding Stock-Based Compensation is defined as the Company's operational expenses in-period excluding treasury value movements and stock-based compensation. It is reconciled to the GAAP measure "Selling, general and administrative expense" by (i) subtracting stock-based compensation expense and (ii) adding Research and development expense. Operating Expenses Excluding Stock-Based Compensation provides a metric of total operating expenditures in-period without the impact of treasury value movement or stock-based compensation, thereby creating a helpful metric for operational expense comparisons between different periods for our management and investors.
    6. "Treasury Gains (Losses)" is a non-GAAP measure. Treasury Gains (Losses) is defined as the gross mark-to-market change in the company's digital asset treasury portfolio each period, without accounting for temporary GAAP impacts due to HYPE to LST conversion (or LST to HYPE reconversion) or operating income driven by airdrops or yield enhancement activity. It is reconciled to the GAAP measure "Net Operating Income (Expenses)" by (a) adding (i) Research and development expense, (ii) Selling, general, and administrative expense, (iii) Provision for credit losses, and (iv) the in-period change in unrealized accretion (dilution) expected upon LST to HYPE reconversion, and (b) subtracting (i) accumulated but unrealized staking yield on LSTs, (ii) operating income from airdrops, and (iii) operating income from yield enhancement strategies. Following these adjustments, Treasury Gains (Losses) is a singular metric that can present mark-to-market treasury changes in isolation, which we believe is a helpful metric for management and investors given our large digital asset treasury position and the volatile nature of digital assets.
    7. "Adjusted Other Income (Expense)" is a non-GAAP measure. Adjusted Other Income (Expense) reflects management's view of recurring activities outside of core operating income and operating expenses. It is reconciled to the GAAP measure "Total Other Income (Expense), Net" by (a) adding back (i) interest expense, (ii) non-recurring gains from reductions in life sciences liabilities, and (iii) other non-recurring items which we do not consider material in nature, and (b) subtracting the portion of GAAP "Interest Income" generated from digital assets receivables. The items added back to Adjusted Other Income (Expense) are excluded because they are non-cash in nature, or because the amount and timing of these items are unpredictable, are not driven by core results of operations, and render comparisons with prior periods and competitors less meaningful. The item subtracted from Adjusted Other Income (Expense) is already captured in the Non-GAAP metric "Adjusted Gross Profit", as further described in Footnote 1. We believe Adjusted Other Income (Expense) provides a helpful view to management and investors regarding recurring and ongoing income and expense items outside of operating income and operating expenses, presented in a way to compare these elements over time.
    8. "Adjusted EBITDA" is a non-GAAP measure. Adjusted EBITDA is meant to reflect management's view of recurring business activities and a more comparable view of the mark-to-market impacts on our digital asset treasury holdings in-period. It is reconciled to the GAAP measure "Net Income (Loss)" by removing (i) stock-based compensation, (ii) interest expense, (iii) provision for credit losses, (iv) income taxes, (v) depreciation and amortization expense (excluding amortization of operating lease), (vi) non-recurring gains from reductions in life sciences liabilities, and (vii) other non-recurring items which we do not consider material in nature; and, it adds the in-period change in unrealized accretion (dilution) expected upon LST to HYPE reconversion. The items excluded from our Adjusted EBITDA are excluded because they are non-cash in nature, or because the amount and timing of these items are unpredictable, are not driven by core results of operations, and render comparisons with prior periods and competitors less meaningful. We add to Adjusted EBITDA the in-period change in unrealized accretion (dilution) expected upon LST to HYPE reconversion to give a more complete picture of mark-to-market impacts on our HYPE holdings, disregarding the temporary impacts of conversion and reconversion between HYPE and LSTs. Adjusted EBITDA is used by management, in addition to GAAP financial measures, to understand and compare our operating results across accounting periods, for risk management and operational decision-making purposes. This non-GAAP measure provides investors with additional information in evaluating the Company's operating performance.
    9. "Net Asset Value" is a non-GAAP measure. Net Asset Value is defined as the market value of our marketable digital assets less net outstanding debt. It is reconciled to the GAAP measure "HYPE digital assets" as adjusted to "Gross HYPE Holdings" (described more fully in Footnote 4) by (i) adding KNTQ digital assets, (ii) adding Current Assets, (iii) subtracting Current Liabilities, and (iv) subtracting Notes Payable (Non-current portion, without subtracting corresponding debt discounts or any unamortized issuance expenses). We believe Net Asset Value is a helpful non-GAAP financial measure to our management and investors because it provides a more complete picture of our net liquid and marketable assets. It does not include Other digital assets which may not be immediately marketable. It does not include other non-current assets or non-current liabilities beyond the aforementioned items. The Company believes Net Asset Value provides useful information about our balance sheet and financial performance, enhances the overall understanding of our past performance and future prospects, allows for greater transparency with respect to important metrics used by our management for financial, risk management and operational decision-making, and provides an additional tool for investors to use to understand and compare our operating results across accounting periods.
    10. Represents in-period accrued staking yield on HYPE LSTs. Staking yield on LSTs is not recognized in-period in accordance with GAAP; instead, LST staking yield may be recognized with an associated realized gain upon future reconversion from LSTs back into HYPE.
    11. Represents the estimated future financial implications if all company-owned LSTs were reconverted to HYPE at the end of each respective period. Encapsulates both the temporary GAAP valuation methodology differences between LSTs and HYPE plus the realization of previously accrued but unrecognized staking yield on LSTs.
    12. In the three months ended September 30, 2025, Gain on extinguishment of liability and a reduction in accrued liability within other income was $2.2 million and $0.2 million respectively, combined totaling $2.4 million.
    13. In the reconciliation of "Total Other Income (Expense), Net" to "Adjusted Other Income (Expense)", as well as in the reconciliation of "Net Income (Loss)" to "Adjusted EBITDA", in the three months ended September 30, 2025, other non-recurring items include gains on sales of equipment, release of reserves held against potential returns of company-sold items, and a one-time realized payment in connection with a terminated LOI. In the three months ended December 31, 2025, other non-recurring items include gains due to valuation differences in the time between contractual and actual delivery dates on certain company-paid expenses denominated in HYPE and in Company equity.
    14. Estimated and unaudited figures as of March 23, 2026.



    Photos accompanying this announcement are available at

    https://www.globenewswire.com/NewsRoom/AttachmentNg/cba563eb-4952-4229-8844-bd018197e857 

    https://www.globenewswire.com/NewsRoom/AttachmentNg/d6a0d72c-5503-4a51-85a5-4d201c6f9674



    Primary Logo

    Get the next $HYPD alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $HYPD

    DatePrice TargetRatingAnalyst
    12/24/2025Buy
    Chardan Capital Markets
    12/16/2025$4.00Overweight
    Cantor Fitzgerald
    More analyst ratings

    $HYPD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

    Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL Tokens as of March 23(14) HYPD's Unique "Triple-Dip" HYPE Deployment Generated ~3x Base Staking Income in Q4 Announces Executed LOI to Monetize the Optejet, With Potential Closing in Q2'26 LAGUNA HILLS, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the fourth quarter and full year ending December 31, 2025. "Against a backdrop of significant market volatility, we are pleased to report rapid

    3/26/26 7:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Enters HAUS Agreement with Silhouette

    LAGUNA HILLS, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that it has entered a HYPE Asset Use Service (HAUS) agreement with Silhouette, a newly launched shielded trading platform built for Hyperliquid. The Company will provide the use of staked HYPE to Silhouette, enabling the exchange's global users to access substantially reduced transaction fees when submitting trades to Hyperliquid via its platform. Silhouette's architecture keeps sophisticated on-chain strategies private, protecting trade information without compromising on execution. "We are excited to work with Silhouette and support their platfor

    3/24/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Schedules Fourth Quarter and Full Year 2025 Earnings Call for Thursday, March 26 at 8:00 a.m. ET

    LAGUNA HILLS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the fourth quarter and full year ended December 31, 2025, on Thursday, March 26, 2026 at 8:00 a.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Date: March 26, 2026Time: 8:

    3/17/26 9:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    General Counsel Rubenstein Robert was granted 75,000 shares (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/12/26 4:02:31 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 3 filed by new insider Rubenstein Robert

    3 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/12/26 4:01:12 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    SEC Filings

    View All

    Hyperion DeFi Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HYPERION DEFI, INC. (0001682639) (Filer)

    3/26/26 7:00:28 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.

    SCHEDULE 13G/A - HYPERION DEFI, INC. (0001682639) (Subject)

    3/3/26 6:00:30 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Hyperion DeFi Inc.

    SCHEDULE 13G/A - HYPERION DEFI, INC. (0001682639) (Subject)

    2/11/26 10:17:17 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Knox David R. bought $100,340 worth of shares (27,950 units at $3.59), increasing direct ownership by 9% to 327,950 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    1/5/26 8:00:09 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $113,091 worth of shares (30,880 units at $3.66), increasing direct ownership by 21% to 91,161 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/30/25 4:01:21 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Strahlman Ellen R bought $120,664 worth of shares (38,444 units at $3.14), increasing direct ownership by 33% to 75,448 units (SEC Form 4)

    4 - HYPERION DEFI, INC. (0001682639) (Issuer)

    12/22/25 8:15:26 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Chardan Capital Markets initiated coverage on Hyperion Defi

    Chardan Capital Markets initiated coverage of Hyperion Defi with a rating of Buy

    12/24/25 11:52:07 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cantor Fitzgerald initiated coverage on Hyperion Defi with a new price target

    Cantor Fitzgerald initiated coverage of Hyperion Defi with a rating of Overweight and set a new price target of $4.00

    12/16/25 8:52:58 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Leadership Updates

    Live Leadership Updates

    View All

    Hyperion DeFi Appoints Hyunsu Jung as Chief Executive Officer

    Board Confirms Leadership Team to Execute 2026 Strategic Priorities Company Also Appoints Robert Rubenstein as General Counsel LAGUNA HILLS, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company") today announced that its Board of Directors has appointed Hyunsu Jung as Chief Executive Officer, effective immediately. Mr. Jung's appointment marks an important milestone in the Company's leadership evolution as it advances its strategic priorities for 2026. Mr. Jung joined Hyperion DeFi as Chief Investment Officer in June 2025, where he has focused on developing on-chain business lines, strengthening operational discipline, and expandin

    1/5/26 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Announces Appointment of David Knox as Chief Financial Officer

    PayPal's Former Head of Capital Markets and Head of Finance for Global Credit and Financial Services Joins Company Strong Advocate for Blockchain Adoption for Traditional Institutional Financial Products LAGUNA HILLS, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ: HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced the appointment of David Knox, CFA, as Chief Financial Officer, effective immediately. This move is part of a broader strategic initiative to strengthen governance and accelerate the Company's decentralized finance ("DeFi") strateg

    9/29/25 8:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $HYPD
    Financials

    Live finance-specific insights

    View All

    Hyperion DeFi Reports 4Q and FY 2025 Financial Results with Quarter-over-Quarter Growth of +64% Revenue and +87% Adjusted Gross Profit

    Five Diversified, Ramping DeFi Business Lines Delivered Growth Exceeding Q4 Guidance Treasury Exceeds 1.93M HYPE, 1.92M KNTQ, & 1.00M HPL Tokens as of March 23(14) HYPD's Unique "Triple-Dip" HYPE Deployment Generated ~3x Base Staking Income in Q4 Announces Executed LOI to Monetize the Optejet, With Potential Closing in Q2'26 LAGUNA HILLS, Calif., March 26, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed DeFi company building on Hyperliquid, today reported results for the fourth quarter and full year ending December 31, 2025. "Against a backdrop of significant market volatility, we are pleased to report rapid

    3/26/26 7:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Schedules Fourth Quarter and Full Year 2025 Earnings Call for Thursday, March 26 at 8:00 a.m. ET

    LAGUNA HILLS, Calif., March 17, 2026 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the fourth quarter and full year ended December 31, 2025, on Thursday, March 26, 2026 at 8:00 a.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Conference Call Information To participate in this event, please log on or dial in approximately 5 minutes before the beginning of the call. Date: March 26, 2026Time: 8:

    3/17/26 9:00:00 AM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hyperion DeFi Schedules Third Quarter 2025 Earnings Call for November 13, 2025

    LAGUNA HILLS, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Hyperion DeFi, Inc. (NASDAQ:HYPD) ("Hyperion DeFi" or the "Company"), the first U.S. publicly listed company dedicated to building a long-term strategic treasury of Hyperliquid's native token, HYPE, today announced that it will hold its earnings conference call and webcast for the third quarter ended September 30, 2025, on Thursday, November 13, 2025 at 5:00 p.m. Eastern Time. A press release detailing these results will be issued prior to the call on the same day. Participants may submit questions in advance of the call via email to [email protected]. A webcast of the call will be archived and available through Thursday, Novembe

    11/3/25 4:00:00 PM ET
    $HYPD
    Biotechnology: Pharmaceutical Preparations
    Health Care